Last week we held a Tweet Chat with our amazing co-hosts Georgia Hurst and Amy Byer Shainman, and special guest Timothy Rebbeck, PhD of the Dana-Farber Cancer Institute to discuss what’s happening in the BRCA world. We had a wonderful, very informative conversation with our community. Here are the highlights of the conversation. Have a question or comment you didn’t get to contribute? Please post in the comments below.

Q1. How do you see #ProphylacticSalpingectomy working into the management plans of #BRCA carriers moving forward?

#Hcchat Q1 1/12: #Salpingectomy involves removing the #FallopianTubes while leaving the #uterus & #ovaries intact.
— Tim Rebbeck (@Vi8tor) October 28, 2015

#Hcchat Q1 4/12: A sizeable proportion of #SerousCarcinomas in #BRCA carriers may arise in the #FallopianTubes, — Tim Rebbeck (@Vi8tor) October 28, 2015

#Hcchat Q1 6/12: Optimal protocol for including #salpingectomy in a risk reduction strategy for #BRCA carriers is not clear at this time.
— Tim Rebbeck (@Vi8tor) October 28, 2015
@ksurkan exactly! Why were some fam members Dx much later, others younger & some not at all? External/environmental factors? #BRCA2#hcchat
— Nicki B. Durlester (@NickiDurlester) October 28, 2015
@ksurkan#hcchat the diagnosis of cancer is later in BRCA2 but we just starting to change recommendations based on these data — Tim Rebbeck (@Vi8tor) October 28, 2015

#Hcchat Q1 9/12: #Salpingectomy may be a useful interim solution for risk reduction but it may not replace the need for #oophorectomy
— Tim Rebbeck (@Vi8tor) October 28, 2015

Q2: What role, if any, do you think #PARPinhibitors will play in the treatment of #BRCA-related cancers in carriers?

#Hcchat Q2 1/7: #PARPinhibitors are drugs that inhibit poly ADP ribose polymerase & are useful in the treatment of BRCA-associated cancers.
— Tim Rebbeck (@Vi8tor) October 28, 2015

#Hcchat Q2 7/7: #Cancer prevention using #PARP inhibitors must assess the benefit vs. potential harms in #BRCA carriers. — Tim Rebbeck (@Vi8tor) October 28, 2015

Aren’t there significant side effects to PARP inhibitors that should be studies b4 prevention use? #hcchat#BRCA
— ksurkan (@ksurkan) October 28, 2015

@NickiDurlester@BRCAresponder@ksurkan@Vi8tor Scientists and patients learning from each other – this is how we make progress! #HCChat — Brave Bosom (@BraveBosom) October 28, 2015

Q3: Do you think #PopulationScreening for #HereditaryCancers will become reality w/in in the next decade?

#Hcchat Q3 2/10: #GeneticTesting should only be done when there is a clear benefit & limited harm. — Tim Rebbeck (@Vi8tor) October 28, 2015

#Hcchat Q3 4/10: Current #GeneticCounseling capacity is not likely to be adequate if population testing were available… — Tim Rebbeck (@Vi8tor) October 28, 2015

@Vi8tor still so many patients still not offered genetictesting after cancer diagnosis with #hereditarycancer factors #Hcchat
— Karen Lazarovitz (@karenBRCAMTL) October 28, 2015

@Vi8tor My concern is psychological impact on patients not prepared for ramifications of + testing results. #Geneticcounseling key! #Hcchat — Nicki B. Durlester (@NickiDurlester) October 28, 2015

Other questions:

@coffeemommy#hcchat Very important point. We need to separate ‘negatives’, ‘true negatives’ and ‘uninformative negatives’.
— Ellen T. Matloff (@MyGeneCounsel) October 28, 2015

@KDeutsch@DanaFarber#hcchat Mutations in other genes appear to confer lower risks than BRCA1/2 but the data are early — Tim Rebbeck (@Vi8tor) October 28, 2015

Shouldn’t there be more discussion about men & their #brca cancer risk? Don’t hear much, or not nearly as much. @Vi8tor#hcchat
— Nancy’s Point (@NancysPoint) October 28, 2015

@coffeemommy#hcchat Through medical education, and public education forums just like this one! Thanks for being a part of the solution. — Ellen T. Matloff (@MyGeneCounsel) October 28, 2015

Read the full transcript here or search #Hcchat on Twitter. Don’t forget to follow us on Twitter and Facebook to receive notifications about upcoming discussions and other news. Also please follow our co-hosts @Shewithlynch and @BRCAresponder and special guest Timothy Rebbeck, PhD.